Your session is about to expire
← Back to Search
APG-157 for Head and Neck Cancer
Study Summary
This trial will study the safety and effectiveness of a new drug, APG-157, as a treatment for head and neck cancer. The hypothesis is that the new drug will reduce the tumor burden and improve outcomes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have newly diagnosed head and neck cancer that has not been treated yet.My doctor considers my mouth or throat condition significant.I can start treatment within 4 weeks of my diagnosis.I have bleeding gums or cracked teeth.I have been diagnosed with oral or throat cancer through a biopsy.I haven't had chemotherapy or radiation in the last 8 weeks.I have had a jaw fracture in the last 8 weeks.My cancer has returned or spread to other parts of my body.I have a tooth abscess.I had oral, dental, or gum surgery in the last 8 weeks.I am scheduled for specific treatments after APG-157, including surgery or radiation for cure or palliation.
- Group 1: APG-157
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there any opportunity for people to participate in this experiment?
"Affirmative. Details found on clinicaltrials.gov show that this medicinal inquiry, which was first published on April 22nd 2022, is currently enlisting participants. A total of 24 volunteers must be sourced from 2 medical facilities."
Is APG-157 a safe option for individuals to consider?
"Given the lack of efficacy information from Phase 2 trials, APG-157 was assigned a score of 2 in terms of safety on our team's scale."
What is the current enrollment of participants in this investigation?
"Affirmative. The clinical trial website displays that this medical research, which was first advertised on April 22nd 2022, is still actively looking for participants. 24 people are required to be found at two different locations."
Share this study with friends
Copy Link
Messenger